Artificial RNA regulators to probe, control, and design gene regulatory networks in bacteria

The project aims to utilize artificial small RNAs to explore gene regulation mechanisms and develop synthetic biology tools, focusing on antibiotic resistance and gene network design.

Subsidie
€ 1.999.913
2023

Projectdetails

Introduction

RNA is common to all organisms. Despite its major function as the coding agent for protein synthesis, an increasing number of regulatory roles have been assigned to RNA. In bacteria, small RNAs (sRNAs) constitute the best-studied class of non-coding regulators estimated to control ~20% of all genes in a given organism. Most sRNAs affect gene expression by base-pairing with multiple target mRNAs resulting in either gene repression or activation.

Characteristics of sRNAs

sRNA regulators are modular, versatile, and highly programmable, and thus have gathered momentum as control devices in synthetic biology and biotechnology.

Recent Developments

My group has recently established artificial sRNAs as a potent genetic tool to screen, detect, and characterize microbial phenotypes. We have now extended this method by a novel sequencing approach, called LIGseq, allowing us to map sRNA-target interactions at the population level and in a high throughput manner.

Applications of sRNAs

We have further shown that sRNAs expressed from the 3’ untranslated regions (UTRs) of mRNAs can serve as tuneable autoregulatory elements and thus bear ample possibilities for the design of artificial gene networks. I therefore posit that artificial sRNAs are powerful, yet understudied control elements of the synthetic biology toolbox with largely untapped regulatory potentials.

Proposed Research Objectives

I thus propose to:

  1. Exploit artificial sRNAs to investigate the molecular principles underlying target selection and RNA duplex formation by bacterial non-coding RNAs.
  2. Harness the power of artificial sRNAs to study essential gene functions and the mechanisms underlying antibiotic resistance in bacteria.
  3. Employ 3’UTR-derived sRNAs as programmable feedback devices in synthetic gene regulatory circuits.

Expected Outcomes

This combined work will generate the molecular framework to employ artificial sRNAs for synthetic biology applications and shed new light on medically relevant processes, such as antibiotic resistance of microbial pathogens.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.913
Totale projectbegroting€ 1.999.913

Tijdlijn

Startdatum1-11-2023
Einddatum31-10-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • FRIEDRICH-SCHILLER-UNIVERSITÄT JENApenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Chemical Tools for Transcriptome-wide Analysis and Modulation of RNA

The RiboChem program aims to develop innovative chemical tools to explore RNA functions and riboswitches, enhancing understanding and targeting for antibiotic development.

€ 1.500.000
ERC Starting...

Designing synthetic regulatory domains to understand gene expression

This project aims to uncover gene regulation mechanisms by systematically altering and analyzing synthetic gene regulatory domains in mouse stem cells to reveal insights into non-coding genome organization.

€ 1.500.000
ERC Advanced...

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

€ 2.500.000
ERC Consolid...

Exploring the expanding universe of RNA-binding proteins in bacteria

This project aims to identify and characterize novel RNA-binding proteins in bacteria using a new capture method to enhance understanding of cellular control and develop targets for industrial and antimicrobial applications.

€ 1.999.625
ERC Consolid...

RNA-based gene writing in human cells

SCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications.

€ 1.999.465